Management of prostate cancer suitable for hormonal manipulation; breast cancer in premenopausal & perimenopausal women suitable for hormonal manipulation; endometriosis including alleviation of symptoms eg, pain & reduction in size & number of lesions. Prethinning of the uterine endometrium prior to endometrial ablation or resection. Assisted reproduction: Pituitary downregulation in prep for superovulation.
1 depot inj SC into the anterior abdominal wall every 28 days. Assisted reproduction Administered as defined by serum oestradiol levels. Take between 7 & 21 days. Endometriosis Duration of treatment: 6 mth. Endometrial thinning 2 depot inj to be administered 4 wk apart w/ surgery timed for between 0 & 2 wk after 2nd depot inj.
Monitor affected patients for signs or symptoms of abdominal haemorrhage. Patient w/ low BMI &/or receiving full anticoagulation medications. Consider & monitor closely men at risk of developing ureteric obstruction or spinal cord compression in the 1st mth of therapy. Increased risk of MI & sudden cardiac death; monitor for CV disease. Reduced bone mineral density. Reduction in glucose tolerance in male receiving LHRH agonists. Monitor blood glucose; stimulation cycle carefully to identify patients at risk of developing OHSS. Women w/ known metabolic bone disease. Androgen therapy may prolong QT interval. Patient w/ history of or risk factors for QT prolongation, receiving medicinal products that may prolong QT interval; assess the benefit-risk ratio including potential for Torsade de Pointes prior to initiation of therapy. Assisted reproduction regimen in patients w/ polycystic ovarian syndrome. Use non-hormonal contraceptive methods during therapy until menses resume. Not to be used during pregnancy. Not recommended during lactation. Not indicated for use in childn.
Sign Out
